- [6] Avouac J, et al. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis* 2006; 65:845

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.7550

AB0271

FACTORS ASSOCIATED WITH HOSPITAL ADMISSIONS MORTALITY IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN. (TREND-AR STUDY)

Ramón Mazzucchelli¹, Elia Perez-Fernandez², Javier Quirós³, Virginia Villaverde⁴, Alberto García-Vadillo⁵, Marina Peña⁶, Carmen Barbadillo⁷, Cristina Macía-Villa⁸, Jose Luis Morell Hita⁹, Hilda Godoy⁷, Manuel Fernandez-Prada¹⁰, María Galindo-Izquierdo¹¹, Angeles Herranz Varela¹², Concepción Morado Quiroga¹³, María Espinosa¹⁴, Cristina Martínez-Prada¹³, Natalia Crespi-Villarias¹⁵. ¹Hospital Universitario Fundación Alcorcón, Rheumatology, Alcorcón, Spain; ²Hospital Universitario Fundación Alcorcón, Clinical Investigation Unit, Alcorcón, Madrid, Spain; ³Hospital Universitario Fundación Alcorcón, Rheumatology, Alcorcón, Spain; ⁴Hospital Universitario de Móstoles, Rheumatology, Móstoles, Spain; ⁵Hospital de La Princesa, Madrid, Spain; ⁶Hospital Universitario Fundación Alcorcón, Rehabilitation, Alcorcón, Spain; ⁷Hospital Puerta de Hierro-Majadahonda, Rheumatology, Majadahonda, Spain; ⁸Hospital Universitario de Leganés, Rheumatology, Leganés, Madrid, Spain; ⁹Hospital Ramón Y Cajal, Rheumatology, Madrid, Spain; ¹⁰Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain; ¹¹University Hospital 12 de Octubre, Rheumatology, Madrid, Spain; ¹²Hospital Henares, Coslada, Spain; ¹³Hospital Clínico Universitario San Carlos, Madrid, Spain; ¹⁴Infanta Sofía University Hospital, Rheumatology, San Sebastián de los Reyes, Spain; ¹⁵Health Center Rivota, Alcorcón, Spain

Background: There have been significant changes in the management of rheumatoid arthritis (RA) during the past 20 years. The potential impact of these changes on hospital admissions mortality is unknown.

Objectives: To analyse the factors associated with hospital admissions mortality in rheumatoid arthritis patients in Spain from 1999 to 2015.

Methods: This is a retrospective population study. We have analyzed a national administrative database that includes a Minimum Basic Data Set (MBDS) of hospital admissions of RA patients during the period 1999 to 2015. We studied all the cases of hospital admissions mortality. Patients were identified by concatenation of clinical record number and birth date. The analyzed factors were identified by the presence in primary and secondary diagnosis of the ICD9 codes, during the first hospital admission. Hazard Ratio (adjusted by sex and age) were calculated using Cox regression analyses.

Results: There were a total of 338.343 hospital admissions in RA patients during the study period, accounting for a total of 186.491 patients (127.203 women (68,21%) and 59.288 men (31,79%). The mean number of hospital admissions was 1,81(SD 1,7), with a minimum of 1 and a maximum of 43. The median time of follow-up was 11,85 months (DE 27,4). There were a total of 18.641 exits (5,5%). The HR (adjusted by sex and age) of the factors associated with hospital admissions mortality are shown in the next table:

Risk factor	Adjusted by sex and age Cox reg analyses		
	HR	IC	p
Gender (Male/Female)	1,242	1,20-1,28	<0,001
Age	1,066	1,064-1,068	<0,001
Charlson Index	1,276	1,268-1,284	<0,001
Stay	1,004	1,003-1,005	<0,001
Cardiovascular disease	1,318	1,274-1,362	<0,001
Dementia	1,852	1,696-2,021	<0,001
Diabetes Mellitus	1,093	1,05-1,137	<0,001
Neoplasm	2,432	2,313-2,556	<0,001
Hepatopathy severe-moderate	3,189	2,752-3,695	<0,001
COPD	1,113	1,071-1,156	<0,001
Pressure ulcers	1,115	1,006-1,235	0,036
Renal Disease	1,758	1,683-1,837	<0,001
Infectious disease during stay	1,593	1,545-1,642	<0,001
S. Felty	1,531	1,18-1,985	<0,001
Amyloidosis	2,957	2,627-3,327	<0,001
Hip fracture	0,731	0,664-0,804	<0,001
Tuberculosis	1,066	1,064-1,068	<0,001

Conclusion: In Spain, during the period of 1999-2015, the factors associated with hospital admission mortality (first admission) are: age, male sex, higher Charlson Index and longer hospital stay. The associated clinical variables are chronic hepatopathy, amyloidosis and neoplasm.

Disclosure of Interests:

None declared

DOI: 10.1136/annrheumdis-2019-eular.2270

AB0272

EVALUATION OF CXCL13, sICAM-1, MMP-3 AND S100A8/A9 AS SERUM BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOLICIZUMAB

D. James Haddon, Thierry Somnasse, Michael J. Townsend, Jinglan Pei, Margaret Michalska. Genentech, Inc., South San Francisco, United States of America

Background: Serum levels of C-X-C motif chemokine ligand 13 (CXCL13) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with response to tocilizumab (TCZ) in patients with rheumatoid arthritis (RA); levels of matrix metalloproteinase-3 (MMP-3) and S100A8/A9 have also been associated with RA disease activity and joint damage.

Objectives: To evaluate the association of CXCL13, sICAM-1, MMP-3 and S100A8/A9 levels with disease activity and response to TCZ in patients with RA who achieved low disease activity with 24 weeks of TCZ + methotrexate (MTX) treatment and were subsequently randomized to TCZ monotherapy (mono) or TCZ + MTX in the COMP-ACT trial (NCT01855789).

Methods: US patients with RA who had an inadequate response to MTX received initial combination therapy of MTX plus TCZ 162 mg subcutaneous for 24 weeks. Patients who achieved Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate (DAS28-ESR) ≤ 3.2 at Week 24 were randomized 1:1 (double-blind) to receive either TCZ mono or continue TCZ + MTX until Week 52. Randomized patients were included in the present study based on baseline, Week 24 and Week 40 sample availability; serum levels of CXCL13, sICAM-1, MMP-3 and S100A8/A9 were measured by immunoassay. Correlations between CXCL13, sICAM-1, MMP-3 and S100A8/A9 levels and DAS28-ESR at baseline, Week 24 and Week 40 were determined according to Spearman correlation coefficient. Changes in CXCL13, sICAM-1, MMP-3 and S100A8/A9 levels from baseline to Week 24 (open-label period) were determined using Wilcoxon test. Mean changes in CXCL13, sICAM-1, MMP-3 and S100A8/A9 levels from Week 24 to Week 40 (randomized period) were compared between treatment arms using analysis of covariance.

Results: Of 296 randomized patients, 249 were included (TCZ mono, n = 126; TCZ + MTX, n = 123). Biomarker levels were well balanced across treatment arms at baseline and Week 24 (randomization). At baseline, there were weak to mild correlations between DAS28-ESR and biomarker levels (CXCL13 [r = 0.13, P = 0.0411], sICAM-1 [r = 0.20, P = 0.0015], MMP-3 [r = 0.19, P = 0.0021], S100A8/A9 [r = 0.25, P = 0.0001]). Significant reductions in mean biomarker levels were observed from baseline to Week 24 (open-label period) among the total randomized patients (P < 0.0001). CXCL13, sICAM-1, MMP-3 and S100A8/A9 levels were relatively stable between Week 24 and Week 40 (randomized period), with no significant differences between TCZ mono and TCZ + MTX (Table).

Table 1. Adverse Events During the 12-Month Post-Index Period, Stratified by OGC Daily Dose

	Dose Q1 ≥ 1.00 to ≤ 13.75 mg N = 184	Dose Q2 > 13.75 to ≤ 25.00 mg N = 184	Dose Q3 > 25.00 to ≤ 40.00 mg N = 198	Dose Q4 > 40 mg N = 161
Patients without type 2 diabetes and without HbA1c ≥ 7.5 in the pre-index period, n	120	136	130	110
With type 2 diabetes diagnosis or HbA1c ≥ 7.5 in the post-index period, n (%)	9 (7.5)	16 (11.8)	16 (12.3)	27 (24.5)
Maximum HbA1c value across HbA1c lab results during post-index, mean (SD)	7.75 (2.46)	8.30 (2.86)	8.25 (2.42)	8.61 (3.09)
Patients with diabetes diagnosis in the pre-index period but without HbA1c ≥ 7.5 in the pre-index period, n	31	18	40	15
With worsening diabetes with HbA1c ≥ 7.5 in the post-index period, n (%)	10 (32.3)	6 (33.3)	20 (50.0)	4 (26.7)
Patients without blood glucose level ≥ 200mg/dL in the pre-index period, n	173	169	179	147
With blood glucose level ≥ 200mg/dL in the post-index period, n (%)	13 (7.5)	15 (8.9)	24 (13.4)	22 (15.0)
Adverse events in the post-index period, n (%)				
Serious infection requiring hospitalization for infection and/or IV antibiotics	31 (16.8)	39 (21.2)	44 (22.2)	40 (24.8)
Serious infection requiring IV antibiotics	29 (15.8)	33 (17.9)	42 (21.2)	35 (21.7)
Serious infection requiring hospitalization for infection	6 (3.3)	12 (6.5)	12 (6.1)	8 (5.0)
Cataracts	22 (12.0)	27 (14.7)	34 (17.2)	35 (21.7)
Gastrointestinal bleeding or ulcer	11 (6.0)	11 (6.0)	13 (6.6)	19 (11.8)
Patients with BMI in pre- and post-index, n	171	162	181	141
Increase in BMI by ≥ 5, n (%)	7 (4.1)	5 (3.1)	9 (5.0)	9 (6.4)

BMI, body mass index; HbA1c, hemoglobin A1c; IV, intravenous; Q, quartile.

Conclusion: In agreement with previous studies, the association between baseline disease activity and CXCL13, sICAM-1, MMP-3 and S100A8/A9 levels was weak to mild; TCZ + MTX treatment from baseline to Week 24 (open-label period) resulted in significant reductions in all biomarkers. Changes in levels of CXCL13, sICAM-1, MMP-3 and S100A8/A9 from Week 24 to 40 (randomized period) were similar between treatment groups, consistent with the finding of non-inferiority of TCZ mono compared with TCZ + MTX in patients with RA who achieve low disease activity with TCZ + MTX.

Acknowledgement: This study was funded by Genentech, Inc.

Disclosure of Interests: D. James Haddon Shareholder of: Stockholder of Genentech/Roche, Employee of: Employee of Genentech/Roche, Thierry